Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Interest & Investment Income (2016 - 2025)

Arrowhead Pharmaceuticals' Interest & Investment Income history spans 13 years, with the latest figure at $9.7 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 27.47% year-over-year to $9.7 million; the TTM value through Dec 2025 reached $39.4 million, up 43.26%, while the annual FY2025 figure was $37.3 million, 64.17% up from the prior year.
  • Interest & Investment Income reached $9.7 million in Q4 2025 per ARWR's latest filing, up from $9.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $11.0 million in Q2 2025 to a low of $1.1 million in Q1 2022.
  • Average Interest & Investment Income over 5 years is $4.7 million, with a median of $4.0 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 49.45% in 2021, then skyrocketed 332.64% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $1.2 million in 2021, then surged by 132.01% to $2.7 million in 2022, then increased by 4.47% to $2.8 million in 2023, then skyrocketed by 171.31% to $7.6 million in 2024, then grew by 27.47% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Interest & Investment Income are $9.7 million (Q4 2025), $9.1 million (Q3 2025), and $11.0 million (Q2 2025).